The Biostatistics and Bioinformatics Gore serves multiple needs for the planning and conduct of the SPORE'S basic and translational research. The Gore provides hypothesis refinement, experimental design, analysis, data management, and informative presentation of results across all projects of the SPORE. From a biostatistical perspective, design and analysis of laboratory and clinical projects are performed at the direction of Dr. Peter Mueller. Dr.
C aimi ao Wei contributes her expertise to the analysis of microarray and genome data in this SPORE. Data from SPORE clinical trials, animal studies, and laboratory experiments are analyzed with the support of Dr. Chariotte Sun, Mr. Mark Munsell, and Ms. Diana Urbauer. Dr. Jonas Almeida will oversee data base management and data integration. Data integration will build on a new deployment of the existing data service SSDB. This SPORE resource is used to augment existing M.D. Anderson biostatistics and bioinformatics resources and to align these considerable resources with SPORE research objectives.
The Specific Aims ofthe Biostatistics and Bioinformatics Gore are:
Specific Aim 1 : To provide guidance in the design and conduct of clinical trials and other experiments arising from the ongoing research ofthe SPORE.
Specific Aim 2 : To provide the innovative statistical modeling, simulation techniques, and data analyses needed by the Projects, Developmental Projects, and other Gores to achieve their Specific Aims.
Specific Aim 3 : To ensure that the results of all Projects are based on well-designed experiments and are appropriately interpreted.
Specific Aim 4 : Provide a web-based environment where data bases can be created and shared within the multi-institutional Uterine SPORE scientific community.

Public Health Relevance

The Biostatics and Bioinformatics Core will provide statistical and bioinformatics analyses as well as data management to all projects, cores, and developmental research and career development program investigators. The Gore will be involved in all aspects of the projects from the developmental to final evaluation stages and will provide the necessary services to ensure high quality analyses for optimal utilization of data resulting from the SPORE studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098258-07
Application #
8321097
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
7
Fiscal Year
2011
Total Cost
$119,406
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Du, Di; Ma, Wencai; Yates, Melinda S et al. (2018) Predicting high-risk endometrioid carcinomas using proteins. Oncotarget 9:19704-19715
Sun, Chaoyang; Yin, Jun; Fang, Yong et al. (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401-416.e8
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Kim, Grace; Kurnit, Katherine C; Djordjevic, Bojana et al. (2018) Nuclear ?-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol 31:1553-1559
Yoo, Jung-Yoon; Kang, Hee-Bum; Broaddus, Russell R et al. (2018) MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. BMC Cancer 18:605
Yuan, Ying; Lin, Ruitao; Li, Daniel et al. (2018) Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res 24:4921-4930
Yates, Melinda S; Coletta, Adriana M; Zhang, Qian et al. (2018) Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila) 11:477-490
Yan, F; Thall, P F; Lu, K H et al. (2018) Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol 29:694-699
Gao, Chao; Wang, Yingmei; Broaddus, Russell et al. (2018) Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget 9:5492-5508
Pan, Haitao; Liu, Suyu; Miao, Danmin et al. (2018) Sample size determination for mediation analysis of longitudinal data. BMC Med Res Methodol 18:32

Showing the most recent 10 out of 578 publications